(Q37687382)

22 August 2017

1 reference

title

Biology and management of inflammatory breast cancer (English)

1 reference

22 August 2017

0 references

1 reference

Shaheenah Dawood

1

1 reference

22 August 2017

publication date

1 February 2010

1 reference

Expert Review of Anticancer Therapy

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

209-220

1 reference

Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute

22 August 2017

cites work

1 reference

Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992.

21 January 2018

1 reference

Population-based statistics for women diagnosed with inflammatory breast cancer (United States).

21 January 2018

1 reference

Epidemiologic features of rapidly progressing breast cancer in Tunisia

21 January 2018

1 reference

Increasing evidence for a human breast carcinoma virus with geographic differences

21 January 2018

1 reference

Inflammatory breast cancer: a review

21 January 2018

1 reference

Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review

21 January 2018

1 reference

Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants

21 January 2018

1 reference

Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast

21 January 2018

1 reference

High incidence of HER-2 positivity in inflammatory breast cancer

21 January 2018

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

Prognostic significance of HER-2 status in women with inflammatory breast cancer

21 January 2018

1 reference

Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6

21 January 2018

1 reference

Mutational spectrum of p53 mutations in primary breast and ovarian tumors.

21 January 2018

1 reference

Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma

21 January 2018

1 reference

In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line

21 January 2018

1 reference

Persistent E-cadherin expression in inflammatory breast cancer

21 January 2018

1 reference

Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.

21 January 2018

1 reference

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

21 January 2018

1 reference

Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression

21 January 2018

1 reference

WISP3 is a novel tumor suppressor gene of inflammatory breast cancer

21 January 2018

1 reference

Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis.

21 January 2018

1 reference

Gene expression profiling identifies molecular subtypes of inflammatory breast cancer

21 January 2018

1 reference

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling

21 January 2018

1 reference

Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis

21 January 2018

1 reference

Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration

21 January 2018

1 reference

Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases

21 January 2018

1 reference

Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings

21 January 2018

1 reference

Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.

21 January 2018

1 reference

Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy

21 January 2018

1 reference

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience

21 January 2018

1 reference

Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center

21 January 2018

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

Long-term results of combined-modality therapy for inflammatory breast carcinoma

21 January 2018

1 reference

Ten-year outcome after combined modality therapy for inflammatory breast cancer.

21 January 2018

1 reference

Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience

21 January 2018

1 reference

Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy

21 January 2018

1 reference

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

21 January 2018

1 reference

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy

21 January 2018

1 reference

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy

21 January 2018

1 reference

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).

21 January 2018

1 reference

Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma

21 January 2018

1 reference

Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.

21 January 2018

1 reference

The role of locoregional therapy in inflammatory breast cancer

21 January 2018

1 reference

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

Pazopanib: a novel multitargeted tyrosine kinase inhibitor

21 January 2018

1 reference

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.90

1 reference

22 August 2017

1 reference